About Erlotinib Tablets 150mg
| Packaging Size |
30 Tablets |
| Strength |
150 mg |
| Brand |
Erlonat |
| Manufacturer |
Natco |
| Form |
Tablet |
| Medicine Type |
Allopathic |
| Packaging Type |
Bottle |
Erlotinib Tablets is used in the treatment of non-small cell lung cancer and pancreatic cancer.
Key Features and ComplianceErlotinib Tablets 150mg are produced under strict cGMP and WHO-GMP guidelines, ensuring high-quality standards for safety and efficacy. The tablets are round, white to off-white, and may feature an identifying code or logo depending on the manufacturer. Each box contains 30 tablets, supporting a month-long regimen under physician supervision. Packaging options include blister packs or boxes, with a shelf life of 24 months.
Therapeutic Applications and BenefitsThese tablets act as epidermal growth factor receptor (EGFR) inhibitors, primarily indicated for adults diagnosed with advanced non-small cell lung cancer or metastatic pancreatic cancer. Erlotinib impedes cancer cell growth by blocking specific signaling pathways, potentially slowing disease progression and improving quality of life for eligible patients.
Usage and Administration GuidelinesErlotinib Tablets are meant for oral intake, commonly at 150mg once daily, as directed by a healthcare provider. To maximize absorption and effectiveness, it is recommended to take the medication on an empty stomach-at least one hour before or two hours after eating. Storage should be at room temperature, in a dry place away from light.
FAQ's of Erlotinib Tablets 150mg:
Q: How should Erlotinib Tablets 150mg be taken for optimal effectiveness?
A: Erlotinib Tablets should be taken orally, once daily, on an empty stomach. It is advisable to take them at least one hour before or two hours after a meal, as directed by your physician, to enhance absorption and effectiveness.
Q: What conditions is Erlotinib 150mg commonly prescribed for?
A: This medication is mainly prescribed for adults with locally advanced or metastatic non-small cell lung cancer and metastatic pancreatic cancer, helping inhibit the growth of cancer cells.
Q: When should Erlotinib not be used?
A: Erlotinib should not be used in individuals with known hypersensitivity to Erlotinib or any of its excipients. Consult your healthcare provider if you have a history of allergic reactions to medications.
Q: Where are Erlotinib Tablets manufactured and can they be exported?
A: Erlotinib Tablets are manufactured in India at facilities compliant with cGMP and WHO-GMP standards. They are available for export to multiple countries, supporting global access to quality oncology medications.
Q: What side effects may occur with Erlotinib Tablets?
A: Common side effects include rash, diarrhea, anorexia, fatigue, and liver function impairment. Any persistent or severe symptoms should be reported to your healthcare professional promptly.
Q: What is the process for obtaining Erlotinib Tablets 150mg?
A: Erlotinib Tablets are prescription-only. A valid prescription from a licensed healthcare provider is required to purchase this medication from authorized pharmacies or exporters.
Q: What benefits can patients expect from Erlotinib treatment?
A: Erlotinib is designed to slow the progression of certain cancers by inhibiting cancer cell growth, potentially improving survival and quality of life for individuals with advanced lung or pancreatic cancer.